4 Largecap Stocks With Price-to-Book Above 20 to Watch for Future Multibagger Potential: Titan, Torrent Pharma, Trent and BSE
- October 21, 2026
- Posted by: Manan Bisht
- Category: Best Stocks
Titan Rs 4,424.20. Torrent Pharma Rs 4,558.70. Trent Rs 2,891.60. BSE Rs 3,336. Market caps from Rs 1.40 lakh crore to Rs 3.95 lakh crore. Data as of 20 Oct 2026.
Quick Answer
Titan, Torrent Pharma, Trent and BSE are the 4 picks in this stocks with price-to-book above 20 watchlist, with market caps between Rs 1.40 lakh crore and Rs 3.95 lakh crore. Titan stands out for the strongest latest-quarter profit growth at 62.88%, while Torrent Pharma offers 20.34% revenue growth in FY26. PE ratios run from 49.55 to 86.64, so compare each one with its industry PE before investing. All figures are as of 20 October 2026.
Stocks with price-to-book above 20 to watch for multibagger potential start with a simple filter: size, a clean financial record and earnings that keep growing. Titan, Torrent Pharma, Trent and BSE meet that test, with market caps from Rs 1.40 lakh crore to Rs 3.95 lakh crore and Titan offering the strongest latest-quarter profit growth at 62.88%. Each of these companies trades at a price-to-book ratio of 20 or more, net profit grew by at least 10 per cent in FY26 and rose in the latest quarter.
This list covers companies with a price-to-book ratio of 20 or more, FY26 profit growth of at least 10 per cent, rising profit in the latest quarter and market capitalisation above Rs 1,00,000 crore. Each company has a market cap above Rs 1 lakh crore. Investors screening stocks with price-to-book above 20 usually begin with size and balance sheet strength, and this list follows the same logic. All figures are as of 20 October 2026 and are drawn from NSE and BSE data and company filings.
Click Here – Get Free Investment Predictions
What Are Stocks With Price-to-Book Above 20 and Why Do They Attract Multibagger Interest?
Stocks with price-to-book above 20 are shares that the market values at many times the accounting value of the business. The four here cover jewellery, pharmaceuticals, retail and a stock exchange.
A price-to-book ratio this high usually goes with strong brands, scarce platforms and high returns. For stocks with price-to-book above 20, the test is whether returns stay high enough to support the premium. For stocks with price-to-book above 20, checking each result against the latest quarter matters more than any single ratio. The next sections explain what stands out in each of stocks with price-to-book above 20, using FY26 and latest quarter data. Prices move daily, so recheck the figures for stocks with price-to-book above 20 before you decide.
Stocks With Price-to-Book Above 20 at a Glance: Price, Market Cap, PE and ROE
Prices are closing prices as of 20 October 2026. BSE combines the lowest PE of the group, 49.55, with the highest return on equity, 37.42%.
| Stock | CMP (Rs) | Market Cap (Rs Cr) | PE | Industry PE | ROE | Debt to Equity | 52-Week Range (Rs) |
|---|---|---|---|---|---|---|---|
| Titan Company | 4,424.20 | 3,94,621 | 68.51 | 46.75 | 32.31% | 0.93 | 3,506.50 to 5,186.70 |
| Torrent Pharmaceuticals | 4,558.70 | 1,75,196 | 81.26 | 36.42 | 25.49% | 1.79 | 3,480.60 to 5,250.00 |
| Trent | 2,891.60 | 1,57,216 | 86.64 | 64.73 | 24.62% | 0.37 | 2,183.67 to 3,399.70 |
| BSE Ltd | 3,336 | 1,39,823 | 49.55 | 42.42 | 37.42% | 0.00 | 2,326.10 to 4,446.80 |
Titan: 23.26% Profit CAGR Since FY22
Titan Company runs the jewellery (Tanishq), watches (Titan), eyewear and fragrances businesses. It reported FY26 revenue of Rs 88,136 crore, up 44.62% year on year, and net profit of Rs 5,073 crore, up 52.02%. Net profit has compounded at 23.26% a year since FY22, while revenue has grown 32.00% a year. Operating margin was 10.06% in FY26.
In the June 2026 quarter, revenue rose 29.31% to Rs 21,502 crore and net profit grew 62.88% to Rs 1,777 crore. The share price has gained 72.39% over five years and 22.47% over the past year. Domestic institutions raised their holding from 12.78% in June 2025 to 15.34% in June 2026. The stock trades at a PE of 68.51 against an industry PE of 46.75, with a return on equity of 32.31%.
Torrent Pharma: 28.79% Profit CAGR Since FY22
Torrent Pharmaceuticals makes branded medicines for chronic therapies such as cardiac, gastro-intestinal and central nervous system care in India and overseas. It reported FY26 revenue of Rs 13,886.15 crore, up 20.34% year on year, and net profit of Rs 2,138.18 crore, up 11.87%. Net profit has compounded at 28.79% a year since FY22, while revenue has grown 12.38% a year. Operating margin was 22.70% in FY26.
The stock trades at a PE of 81.26 against an industry PE of 36.42, with a return on equity of 25.49%. In the June 2026 quarter, revenue rose 56.29% to Rs 4,909 crore and net profit grew 3.28% to Rs 566 crore. The share price has gained 194.63% over five years and 29.72% over the past year. Domestic institutions raised their holding from 9.28% in September 2025 to 12.87% in July 2026.
Trent: Return on Equity of 24.62%
Trent runs the Westside, Zudio and Star retail chains selling fashion, apparel and grocery products. It reported FY26 revenue of Rs 20,189.05 crore, up 16.34% year on year, and net profit of Rs 1,721.33 crore, up 12.18%. Revenue has compounded at 44.17% a year since FY22. Operating margin was 17.91% in FY26. The debt-to-equity ratio is 0.37.
In the June 2026 quarter, revenue rose 17.47% to Rs 5,784.54 crore and net profit grew 21.98% to Rs 518.07 crore. The share price has gained 283.92% over five years. Domestic institutions raised their holding from 19.98% in September 2025 to 23.33% in September 2026. The stock trades at a PE of 86.64 against an industry PE of 64.73, with a return on equity of 24.62%.
BSE: 78.30% Profit CAGR Since FY22
BSE Ltd operates one of India’s two major stock exchanges and earns from trading, listing, data and clearing services. It reported FY26 revenue of Rs 5,148.10 crore, up 59.07% year on year, and net profit of Rs 2,475.30 crore, up 87.94%. Net profit has compounded at 78.30% a year since FY22, while revenue has grown 56.26% a year. Operating margin was 68.39% in FY26. The debt-to-equity ratio is 0.00, which keeps interest costs low.
The stock trades at a PE of 49.55 against an industry PE of 42.42, with a return on equity of 37.42%. In the June 2026 quarter, revenue rose 63.41% to Rs 1,706.72 crore and net profit grew 62.15% to Rs 872.66 crore. The share price has gained 2101.66% over five years and 37.49% over the past year. Domestic institutions raised their holding from 13.51% in June 2025 to 24.15% in June 2026.
Stocks With Price-to-Book Above 20: Financial Comparison on Growth and Margins
The table compares scale and growth across these stocks with price-to-book above 20. Latest quarter means the most recent reported quarter for each company, and only metrics that are positive for every company are shown.
| Stock | Revenue (Rs Cr) | Net Profit (Rs Cr) | Revenue Growth (YoY) | 4-Year Revenue CAGR | Latest Quarter Revenue Growth | Operating Margin (Latest Quarter) |
|---|---|---|---|---|---|---|
| Titan | 88,136 | 5,073 | 44.62% | 32.00% | 29.31% | 14.61% |
| Torrent Pharma | 13,886.15 | 2,138.18 | 20.34% | 12.38% | 56.29% | 33.73% |
| Trent | 20,189.05 | 1,721.33 | 16.34% | 44.17% | 17.47% | 19.97% |
| BSE | 5,148.10 | 2,475.30 | 59.07% | 56.26% | 63.41% | 77.03% |
Check the Univest Screener for live data on these stocks with price-to-book above 20
Institutional Holding in Titan, Torrent Pharma, Trent and BSE
Institutional holding shows who is backing these stocks with price-to-book above 20 alongside the promoter. The table uses the latest reported quarter for each. BSE has the deepest institutional backing, with FII and DII together holding 45.47% as of June 2026. Domestic institutions increased their holding over the past year in Titan (from 12.78% to 15.34%), Torrent Pharma (from 9.28% to 12.87%), Trent (from 19.98% to 23.33%) and BSE (from 13.51% to 24.15%).
| Stock | Promoter | FII | DII | Public | Quarter |
|---|---|---|---|---|---|
| Titan | 52.90% | 15.38% | 15.34% | 16.38% | June 2026 |
| Torrent Pharma | 60.78% | 17.97% | 12.87% | 8.38% | July 2026 |
| Trent | 37.01% | 15.28% | 23.33% | 24.39% | September 2026 |
| BSE | Nil | 21.32% | 24.15% | 54.53% | June 2026 |
Risks to Weigh in Stocks With Price-to-Book Above 20
Being careful with stocks with price-to-book above 20 means looking at what can slow the story as well as what can speed it up. Four points matter most:
- Past growth may not repeat.
- Share prices can move sharply in either direction.
- Valuation: Torrent Pharma trades at a PE of 81.26 against an industry PE of 36.42, so earnings need to keep growing to support the price.
- Concentration: Holding all 4 names puts the allocation in one sector, so size each position to match your risk appetite.
How to Choose Between Stocks With Price-to-Book Above 20
Picking from stocks with price-to-book above 20 comes down to four checks, applied in order.
- Check balance sheet strength first, and prefer a debt-to-equity ratio below 1 for non-financial companies.
- Compare each PE with the industry PE (36.42 to 64.73) and ask whether the growth rate justifies any gap.
- Track net profit growth, the operating margin and the return on equity in every quarterly result.
- Stagger entries across quarters and review institutional holding every reporting season.
Download the Univest iOS App or Univest Android App to track Titan, Torrent Pharma, Trent and BSE live prices.
Conclusion
Among stocks with price-to-book above 20, Titan stands out for the strongest latest-quarter profit growth at 62.88%, Torrent Pharma for 20.34% revenue growth in FY26, Trent for 16.34% revenue growth in FY26 and BSE for the highest return on equity at 37.42%. Which one suits a portfolio depends on how much valuation risk it can carry, so staggering entries and reviewing each quarterly result is a sound habit. Investors comparing stocks with price-to-book above 20 should rank them on growth, financial strength and the price paid, and anyone who wants personalised guidance can consult a SEBI-registered advisor before acting.
Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).
Frequently Asked Questions on Stocks With Price-to-Book Above 20 to Watch
Which are the best stocks with price-to-book above 20 to watch for multibagger potential?
Ans. Titan, Torrent Pharma, Trent and BSE are the 4 names this list highlights, with market caps of Rs 3,94,621 crore, Rs 1,75,196 crore, Rs 1,57,216 crore and Rs 1,39,823 crore respectively. Titan is notable for the strongest latest-quarter profit growth at 62.88%. Torrent Pharma stands out for 20.34% revenue growth in FY26. Trent offers 16.34% revenue growth in FY26. BSE brings the highest return on equity at 37.42%. These are watchlist names for stocks with price-to-book above 20, not recommendations, so match each one to your own risk profile and time horizon.
Is BSE a good stock for long-term investors?
Ans. BSE has a return on equity of 37.42%, a PE of 49.55 against an industry PE of 42.42 and a market cap of Rs 1,39,823 crore. Net profit has compounded at 78.30% a year since FY22, and FY26 revenue rose 59.07% while June 2026 quarter net profit grew 62.15%. Long-term returns in stocks with price-to-book above 20 depend on earnings growth and the price paid at entry, so staggering purchases and consulting a SEBI-registered advisor is sensible.
Can Torrent Pharma become a multibagger from here?
Ans. Torrent Pharma has already gained 194.63% in five years, so another multi-fold move would need sustained earnings growth. A multibagger outcome in stocks with price-to-book above 20 requires earnings to keep growing faster than the market for several years. Net profit has compounded at 28.79% a year since FY22, and FY26 revenue rose 20.34%. At a PE of 81.26 against an industry PE of 36.42, valuation should be checked against that growth before investing.
What is the market cap of Titan, Torrent Pharma, Trent and BSE?
Ans. As of 20 October 2026, Titan has a market cap of Rs 3,94,621 crore, Torrent Pharma has a market cap of Rs 1,75,196 crore, Trent has a market cap of Rs 1,57,216 crore and BSE has a market cap of Rs 1,39,823 crore. All of them qualify as largecaps. Market cap changes daily with the share price, so check the latest figure on the Univest Screener or on NSE before taking a decision on stocks with price-to-book above 20.
What are the risks of investing in stocks with price-to-book above 20?
Ans. The main risks are market swings, slower growth than expected and valuations that already reflect good news. Companies with strong balance sheets and steady earnings handle these better. Torrent Pharma trades at a PE of 81.26 against an industry PE of 36.42, so earnings growth needs to hold up.
Why is Torrent Pharma trading at a PE of 81.26?
Ans. Torrent Pharma’s PE of 81.26 compares with an industry PE of 36.42. The market is paying a premium for a return on equity of 25.49%, profit growth of 28.79% a year since FY22 and FY26 revenue growth of 20.34%, which also means the stock is more sensitive if growth slows. Investors in stocks with price-to-book above 20 who are comfortable with higher valuation risk may prefer to stagger purchases instead of investing in one go.
How much do institutions hold in Titan, Torrent Pharma, Trent and BSE?
Ans. As of the latest reported quarter, FII and DII together hold 30.72% of Titan (15.38% and 15.34%), 30.84% of Torrent Pharma (17.97% and 12.87%), 38.61% of Trent (15.28% and 23.33%) and 45.47% of BSE (21.32% and 24.15%). Rising institutional holding is a useful signal in stocks with price-to-book above 20, though it should be read with earnings trends rather than on its own.
